Contract Development Services

Drug Solutions Podcast: 2022 Bio/pharma Trends: US-Based Suppliers, Digitization, and Sustainability

January 18, 2022

In this episode of the Drug Solutions podcast, Chris Spivey, editorial director, and Meg Rivers, senior editor, interview experts on up-and-coming 2022 trends in the bio/pharma industry.

Sterling Pharma Solutions Invests in Process Development and Manufacturing in Dudley, UK

November 19, 2021

Sterling Pharma Solutions has announced a £10 million (US$13.5 million) investment into process development and manufacturing capacity at its site in Dudley, UK.

The Earlier the Better for Formulation Strategies

November 03, 2021

Investing in formulation strategies earlier on in development will maximize the chance of success.

Putting the Patient at the Heart of Dosage Form Design

August 03, 2021

Dosage form priorities are shifting to focus on user-friendliness, leading to greater engagement with outsourcing partners earlier in development timelines.

Developing the Best Formulation Partnership

August 02, 2021

Collaborative partnerships can foster success in formulation development projects.

Integrated Approach Facilitates Inhalation Drug Development

August 01, 2021

The choice of delivery platform for inhaled drug products is contingent on API-related factors, as well as the development stage of the product.

Pharma Services Sector Poised for Continued Growth and Consolidation

August 01, 2021

The CRO market will see greater consolidation by both financial buyers looking to consolidate smaller players and larger CRO players wanting to expand into value-added specialty service areas.

Lonza and CellPoint Collaborate to Develop T-cell Based Therapies

June 24, 2021

The companies will utilize the Cocoon Platform for clinical point-of-care manufacturing.

SelectImmune and Lonza to Develop Immunotherapeutic Drug Candidate

June 24, 2021

The companies have entered into an agreement to develop processes for a novel immunotherapy protein.

Vectura Signs Agreement with Incannex to Advance TBI Treatment

June 22, 2021

Vectura has signed an agreement with Incannex Healthcare for the pre-clinical development of IHL-216A, an inhaled drug product for the treatment of traumatic brain injury.